Akari Therapeutics Plc announced it raised $12.8 Million in an initial filing from an offering of $12.8 Million

Company

Location

About

Akari Therapeutics is an oncology biotech company developing novel antibody drug conjugates (ADCs) with its first payload, PH1, a spliceosome modulator that disrupts RNA splicing in cancer cells. Unlike traditional ADC payloads, PH1 induces cancer cell death while activating immune responses, showing robust and durable activity in preclinical models.